Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease

Scott E. Counts, Balmiki Ray, Elliott J. Mufson, Sylvia E. Perez, Bin He, Debomoy K. Lahiri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.

Original languageEnglish (US)
Pages (from-to)S80-S85
JournalJournal of Clinical Immunology
Volume34
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 2014

Fingerprint

Intravenous Immunoglobulins
Alzheimer Disease
Antioxidants
Defense Mechanisms
Oxidants
Neurodegenerative Diseases
Oxidative Stress
Neurons
Brain

Keywords

  • Alzheimer's disease
  • Human neurons
  • Immunoglobulin
  • Neuroprotection
  • Oxidative stress
  • Transgenic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. / Counts, Scott E.; Ray, Balmiki; Mufson, Elliott J.; Perez, Sylvia E.; He, Bin; Lahiri, Debomoy K.

In: Journal of Clinical Immunology, Vol. 34, No. SUPPL. 1, 07.2014, p. S80-S85.

Research output: Contribution to journalArticle

Counts, Scott E. ; Ray, Balmiki ; Mufson, Elliott J. ; Perez, Sylvia E. ; He, Bin ; Lahiri, Debomoy K. / Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. In: Journal of Clinical Immunology. 2014 ; Vol. 34, No. SUPPL. 1. pp. S80-S85.
@article{267a0f2ae5a247d09c723e0f04d9eb2f,
title = "Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease",
abstract = "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.",
keywords = "Alzheimer's disease, Human neurons, Immunoglobulin, Neuroprotection, Oxidative stress, Transgenic",
author = "Counts, {Scott E.} and Balmiki Ray and Mufson, {Elliott J.} and Perez, {Sylvia E.} and Bin He and Lahiri, {Debomoy K.}",
year = "2014",
month = "7",
doi = "10.1007/s10875-014-0020-9",
language = "English (US)",
volume = "34",
pages = "S80--S85",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease

AU - Counts, Scott E.

AU - Ray, Balmiki

AU - Mufson, Elliott J.

AU - Perez, Sylvia E.

AU - He, Bin

AU - Lahiri, Debomoy K.

PY - 2014/7

Y1 - 2014/7

N2 - Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.

AB - Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.

KW - Alzheimer's disease

KW - Human neurons

KW - Immunoglobulin

KW - Neuroprotection

KW - Oxidative stress

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=84905087145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905087145&partnerID=8YFLogxK

U2 - 10.1007/s10875-014-0020-9

DO - 10.1007/s10875-014-0020-9

M3 - Article

C2 - 24760109

AN - SCOPUS:84905087145

VL - 34

SP - S80-S85

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - SUPPL. 1

ER -